ClinicalTrials.gg
CompletedNCT02723994Updated Mar 11, 2026

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

A Phase 2 interventional study of Ruxolitinib and Asparaginase Erwinia Chrysanthemi in Leukemia, sponsored by Incyte Corporation. Completed at 111 sites in 3 countries. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
171
Allocation
Not applicable
Ages
1 Year to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing ruxolitinib in Leukemia — 3 open to participants now, 5 under way, 1 of them phase 3. ruxolitinib · Leukemia.

Enrollment
2nd of 10
171 · median 47
Started
2016
the only one that year
Phase 2
4 of 10
2 open now
Registered
5th of 10
by date
Lead sponsor
1 of 10
Incyte Corporation

Among the 10 studies testing ruxolitinib in Leukemia, this one is the 2nd largest by enrollment, is the only one that started in 2016, is one of 4 in phase 2, and was the 5th registered.

Leukemia

2,382 studies on the registry are indexed under Leukemia; 254 are open to participants now.

Browse Leukemia studies →

Open to participants now

3 of the 10 studies testing ruxolitinib in Leukemia are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Leukemia studies recruiting now, 112 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 86 take children under 18; 24 take healthy volunteers.

This study: 1 Year to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ruxolitinib in Leukemia, or all of them as a file.
02

Study summary

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.

03

Conditions studied

  • Leukemia

Keywords

  • B-cell acute lymphoblastic leukemia (ALL)
  • pediatric
  • multi-agent chemotherapy
  • JAK inhibitor
04

Who can participate

Ages eligible
1 Year to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible for study when participant is 1 year to 21 years at the time of diagnosis
  • Eligible Ages in Canada; 2 years to 21 years
  • De novo high-risk (HR) Ph-like B-ALL for which any of following criteria are present at diagnosis:

    • Age ≥ 10 years
    • White blood cell (WBC) ≥ 50 × 10\^3/μL
    • CNS3 leukemia at diagnosis
    • Systemic pretreatment without presteroid WBC documentation
  • Diagnostic bone marrow or peripheral blood sample must have gene expression profiling and downstream genetic testing performed by submitting diagnostic specimens under the COG AALL08B1 or APEC14B1 biology studies, or AALL1131 or its successor study. Specimens must demonstrate a Ph-like expression profile (ie, LDA-positive) as tested by low density microarray testing at the COG ALL reference laboratory or TriCore laboratory at the University of New Mexico AND must contain 1 of the following genetic lesions: (determined at COG ALL reference laboratories, or equivalent CAP/CLIA-certified laboratories approved by the medical monitor:

    1. CRLF2 rearrangement with confirmed JAK1 or JAK2 mutation (JAK+)
    2. CRLF2 rearrangement without JAK mutation
    3. Other JAK pathway alterations (eg, JAK2 fusions, EPOR fusions, SH2B3 deletions, IL7RA mutations) with or without CRLF2-R, or CRLF2-R with unknown JAK status as determined by a COG ALL Reference Laboratory
  • Completed a 4-drug Induction therapy regimen (modified aBFM regimen or equivalent) in Study AALL1131 or its successor study, or as per the institutional standard of care for HR B-ALL and have had end-Induction minimal residual disease (MRD) assessed
  • Male and female subjects of reproductive non or willing to take appropriate precautions to avoid pregnancy or fathering a child for the duration of study participation

Exclusion criteria

Exclusion Criteria:

  • Receipt of any other cytotoxic chemotherapy before Induction therapy, with exception of hydroxyurea or pretreatment
  • Trisomy 21 (Down syndrome)
  • BCR-ABL1-rearranged (Ph+) ALL
  • Calculated or radioisotope \< 70 mL/min/1.73 m\^2
  • ≥ 5 × (ULN) for age
  • Direct ≥ 1.5 × ULN (may be assumed if total bilirubin is below ULN)
  • History or evidence of cirrhosis
  • count \< 75 × 10\^3/μL
  • (ANC) \< 750/μL
  • Positive screen for or C
  • Known infection
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    Ruxolitinib in combination with chemotherapy

    Drug: Ruxolitinib · Drug: Asparaginase Erwinia Chrysanthemi · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Dexamethasone · Drug: Doxorubicin · Drug: Leucovorin Calcium · Drug: Mercaptopurine · Drug: Methotrexate · Drug: Pegaspargase · Drug: Prednisone · Drug: Thioguanine · Drug: Vincristine Sulfate

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Safety/tolerability of ruxolitinib in combination with chemotherapy as measured by adverse events (AEs), vital signs, clinical laboratory tests, and echocardiograms

    Time frame: Part 1: AEs assessed from screening through up to 30 days after the last dose of study drug, expected to be 26 months (females) or 38 months (males)

  2. Part 2: Efficacy of ruxolitinib in combination with chemotherapy as measured by Event-free survival, defined as the percentage of patients alive without relapse, progression, or death at 3 years from study Day 1

    Time frame: Part 2: assessed at 3 years

Secondary outcomes

  1. Safety and tolerability of the combination treatment for subjects beginning treatment at the recommended dose for Part 2, as assessed by AEs, vital signs, clinical laboratory tests, and echocardiograms

    Time frame: AEs assessed from screening through up to 30 days after the last dose of study treatment, expected to be 26 months (females) or 38 months (males)

07

Study locations

111 sites
  • The Childrens Hospital of Alabama
    Birmingham, Alabama 35233, United States
  • Phoenix Children'S Hospital
    Phoenix, Arizona 85016-7710, United States
  • Arkansas Childrens Hospital
    Little Rock, Arkansas 72202, United States
  • Kaiser Permanente
    Fontana, California 92335, United States
  • Loma Linda University Cancer Center
    Loma Linda, California 92350, United States
  • Miller Childrens Hospital Pharmacy
    Long Beach, California 90806, United States
  • Children'S Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Kaiser Foundation Health Plan
    Los Angeles, California 90027, United States
  • Southern California Permanente Medical Group
    Los Angeles, California 90027, United States
  • Valley Childrens Hospital
    Madera, California 93636-8762, United States
  • Choc Children Hospital
    Orange, California 92868, United States
  • Lucille Packard Childrens Hospital
    Palo Alto, California 94304, United States
  • Kaiser Permanente
    San Diego, California 92111, United States
  • Rady Children'S Hospital - San Diego
    San Diego, California 92123, United States
  • Ucsf Pediatric Oncology
    San Francisco, California 94158, United States
  • Kaiser Permanente Downey
    Santa Fe Springs, California 90670, United States
  • Children'S Hospital Colorado
    Aurora, Colorado 80045, United States
  • Connecticut Children'S Medical Ctr
    Hartford, Connecticut 06106, United States
  • Smilow Cancer Center - Yale
    New Haven, Connecticut 06510, United States
  • Alfred I. Dupont Hospital For Children
    Wilmington, Delaware 19803, United States
  • Childrens Hospital of Southwest Florida
    Fort Myers, Florida 33908, United States
  • Joe Dimaggio Children Hospital
    Hollywood, Florida 33021, United States
  • Nemours Childrens Clinic
    Jacksonville, Florida 32207, United States
  • University of Florida Health Shands Hospital
    Jacksonville, Florida 32209, United States
  • Florida Hospital Orlando
    Orlando, Florida 32803, United States
  • Arnold Palmer Hospital For Children
    Orlando, Florida 32806, United States
  • Nemours Childrens Clinic
    Pensacola, Florida 32504, United States
  • All Childrens Hospital
    St. Petersburg, Florida 33701, United States
  • St Josephs Childrens Hospital Tampa
    Tampa, Florida 33607, United States
  • Saint Marys Medical Center
    West Palm Beach, Florida 33407, United States
  • Egleston Children'S Health
    Atlanta, Georgia 30322-1060, United States
  • Kapiolani Medical Center For Women and Children
    Honolulu, Hawaii 96826, United States
  • Ann & Robert H. Lurie Children'S Hospital
    Chicago, Illinois 60611, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153-3328, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • Riley Hospital For Children
    Indianapolis, Indiana 46202, United States
  • St Vincent Hospital
    Indianapolis, Indiana 46260, United States
  • Blank Childrens Hospital
    Des Moines, Iowa 50309, United States
  • University of Iowa Hospital and Clinics
    Iowa City, Iowa 52242, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Kosair Childrens Hospital
    Louisville, Kentucky 40202, United States
  • Ochsner Clinic
    New Orleans, Louisiana 70121, United States
  • Maine Center For Cancer Medicine
    Scarborough, Maine 04074, United States
  • Sinai Hospital of Baltimore
    Baltimore, Maryland 21215, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287-7049, United States
  • Dana Farber Boston Children'S
    Boston, Massachusetts 02215, United States
  • Cs Mott Childrens Hospital
    Ann Arbor, Michigan 48109, United States
  • Helen Devos Childrens Hosp
    Grand Rapids, Michigan 49503, United States
  • Michigan State University
    Lansing, Michigan 48912, United States
  • Children'S Hospitals and Clinics of Minnesota
    Minneapolis, Minnesota 55404, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • The Children'S Mercy Hospital Outpatient
    Kansas City, Missouri 64108, United States
  • Washington University
    St Louis, Missouri 63130, United States
  • Children'S Hospital & Medical Center
    Omaha, Nebraska 68114, United States
  • Alliance For Childhood Diseases
    Las Vegas, Nevada 89109, United States
  • Children'S Center For Cancer & Blood Dis
    Las Vegas, Nevada 89109, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Morristown Medical Center
    Morristown, New Jersey 07962, United States
  • Rutgers Cancer Institute of Nj
    New Brunswick, New Jersey 08901, United States
  • Newark Beth Israel Medical Center
    Newark, New Jersey 07112, United States
  • St Josephs Regional Medical Center
    Paterson, New Jersey 07503, United States
  • University of New Mexico Hospital
    Albuquerque, New Mexico 87131, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14263, United States
  • Cohen Children'S Medical Center
    New Hyde Park, New York 11040, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Nyu Clinical Cancer Center
    New York, New York 10032, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Suny Upstate Medical University
    Syracuse, New York 13210, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • University of North Carolina At Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Carolinas Medical Center
    Charlotte, North Carolina 28203, United States
  • Wake Forest University
    Winston-Salem, North Carolina 27157, United States
  • Akron Children'S Hospital
    Akron, Ohio 44308, United States
  • Cincinnati Childrens Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Rainbow Babies & Children Hosp
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Nationwide Children'S Hospital
    Columbus, Ohio 43205, United States
  • Dayton Children'S Hospital
    Dayton, Ohio 45404, United States
  • Toledo Hospital
    Toledo, Ohio 43606, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Legacy Emanuel Hospital and Health Center
    Portland, Oregon 97227, United States
  • Doernbecher Childrens Hospital
    Portland, Oregon 97239, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033-2360, United States
  • Children'S Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Childrens Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Hasbro Childrens Hospital
    Providence, Rhode Island 02903, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Dell Childrens Medical Center of Central Texas
    Austin, Texas 78723, United States
  • Driscoll Children'S Hospital
    Corpus Christi, Texas 78411, United States
  • Medical City Dallas Hospital
    Dallas, Texas 75230, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • El Paso Children'S Hospital Corporation
    El Paso, Texas 79905, United States
  • Texas Childrens Hospital
    Houston, Texas 77030, United States
  • University of Texas Health Science Cente
    San Antonio, Texas 78229, United States
  • Primary Children'S Hospital
    Salt Lake City, Utah 84113, United States
  • Children'S Hospital of the
    Norfolk, Virginia 23507, United States
  • Seattle Children'S Hospital
    Seattle, Washington 98105, United States

Showing the first 100 of 111 sites across 3 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Mar 2026, 113 months.

Of 32 industry-sponsored phase 2 interventional studies under Leukemia, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 61. This study's 113 months is above that.

Counting every sponsor, half of 176 studies reached it within 76 months; a quarter within 44 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2016
First posted
Mar 31, 2016
StartActual
Sep 30, 2016
Primary completionActual
Mar 3, 2026
CompletionActual
Mar 3, 2026
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02723994
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Mar 31, 2016
Start date
Sep 30, 2016
Primary completion
Mar 3, 2026
Completion
Mar 3, 2026
Last update
Mar 11, 2026

Study contacts

Albert Assad, MD
study director · Incyte Corporation
Sarah Tasian, MD
study chair · Children's Hospital of Philadelphia, Philadelphia, PA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion